SCHEMBL789909

SCHEMBL789909

Cc1ccccc1OP(=S)(Cl)Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ACHE P22303 1/20 0.38
MAPT P10636 1/20 0.37
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
CYP1A2 P05177 3/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
NOTUM Q6P988 1/20 0.35
SCN4A P35499 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NISCH Q9Y2I1 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5851928 0.87 MAPT (0.41) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL7100690 0.82 TSHR (0.43) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL29581117 0.82 TSHR (0.43) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL5851935 0.79 TSHR (0.38) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL3762100 0.78 KDM4E (0.47) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL31081497 0.78 KDM4E (0.47) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL29247987 0.78 TSHR (0.41) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL2853559 0.78 KDM4E (0.47) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL30320756 0.78 TSHR (0.41) KMT2ATSHRMEN1NPC1RAB9A
SCHEMBL11698433 0.78 CA1 (0.56) KMT2ATSHRMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9278990-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2016-03-08 US disclosed
US-9278990-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2016-03-08 US disclosed
US-20150038451-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. 2015-02-05 US disclosed
US-20150038451-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. 2015-02-05 US disclosed
US-8871737-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-10-28 US disclosed
US-8871737-B2 Substituted nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-10-28 US disclosed
WO-2012040127-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-29 WO disclosed
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 US disclosed
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 US disclosed
US-5804569-A ANTIINFLAMMATORY, ANTIARRHYMIC AND LOCAL ANESTHETIC AGENT CLARION PHARMACEUTICALS INC. (US) 1998-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071434-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NUDT1, TYMP KMT2A 1930/4885TSHR 2346/4885MEN1 1839/4885
US-20150038451-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NUDT1, TYMP KMT2A 1930/4885TSHR 2346/4885MEN1 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.